China: Food, Drugs, Healthcare, Life Sciences

China's regulators intensified anti-corruption enforcement in the life sciences sector during the first half of 2026, introducing stricter oversight of medical data security, sales representatives, and public procurement processes. New administrative measures and judicial interpretations have lowered thresholds for criminal liability while expanding corporate accountability for employee misconduct.

The US Department of Health and Human Services has launched Operation TrialBlazer to address China's growing dominance in clinical research and restore American leadership in biomedical innovation. As Chinese clinical trials now surpass US trials in both speed and volume, this comprehensive initiative aims to modernize regulatory processes, reduce administrative burdens, and reverse the trend of research investment flowing overseas.

上述孙文和蒋文均聚焦于《专利审查指南》第五部分第九章第3.5节“新药相关技术方案应当以国务院药品监督管理部门批准的新药的结构、组成及其含量，批准的生产工艺和适应症为准。指定权利要求未包括获得上市许可的新药相关技术方案的，不予期限补偿”的规定，进行分析和论证，然而

China's regulators intensified anti-corruption enforcement in the life sciences sector during the first half of 2026, introducing stricter oversight of medical data security, sales representatives, and public procurement processes. New administrative measures and judicial interpretations have lowered thresholds for criminal liability while expanding corporate accountability for employee misconduct.

Patent applications for biomarkers in disease diagnosis are rapidly growing, yet many fail to meet patent law requirements. While screening experiments can identify correlations between biomarkers and diseases, they alone cannot prove diagnostic value. This analysis examines why validation experiments demonstrating sensitivity and specificity are essential for patent approval, and how their absence leads to rejection under Chinese Patent Law Articles 26(3) and 26(4).

The US Department of Health and Human Services has launched Operation TrialBlazer to address China's growing dominance in clinical research and restore American leadership in biomedical innovation. As Chinese clinical trials now surpass US trials in both speed and volume, this comprehensive initiative aims to modernize regulatory processes, reduce administrative burdens, and reverse the trend of research investment flowing overseas.

China's regulators intensified anti-corruption enforcement in the life sciences sector during the first half of 2026, introducing stricter oversight of medical data security, sales representatives, and public procurement processes. New administrative measures and judicial interpretations have lowered thresholds for criminal liability while expanding corporate accountability for employee misconduct.

商业经营中，企业惯于用资产负债表衡量有形成本与收益，却很少将员工的心理健康纳入管理视野——这是一项被长期忽略的“隐形负债”。国际劳工组织（ILO）在2026年4月发布的最新全球报告显示，工作相关的心理社会风险因素每年导致超过84万人死于相关的心血管疾病和精神障碍，同时导致全ங

The US Department of Health and Human Services has launched Operation TrialBlazer to address China's growing dominance in clinical research and restore American leadership in biomedical innovation. As Chinese clinical trials now surpass US trials in both speed and volume, this comprehensive initiative aims to modernize regulatory processes, reduce administrative burdens, and reverse the trend of research investment flowing overseas.